Cargando…

Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa

Background. A new group A meningococcal conjugate vaccine was developed to eliminate deadly meningitis epidemics in sub-Saharan Africa. Methods. From the outset of the project, advocacy and communication strategies were developed and adjusted as the project evolved in Europe, Africa, India, and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Berlier, Monique, Barry, Rodrigue, Shadid, John, Sirica, Coimbra, Brunier, Alison, Hasan, Hayatee, Bouma, Enricke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639482/
https://www.ncbi.nlm.nih.gov/pubmed/26553674
http://dx.doi.org/10.1093/cid/civ493
_version_ 1782399920070721536
author Berlier, Monique
Barry, Rodrigue
Shadid, John
Sirica, Coimbra
Brunier, Alison
Hasan, Hayatee
Bouma, Enricke
author_facet Berlier, Monique
Barry, Rodrigue
Shadid, John
Sirica, Coimbra
Brunier, Alison
Hasan, Hayatee
Bouma, Enricke
author_sort Berlier, Monique
collection PubMed
description Background. A new group A meningococcal conjugate vaccine was developed to eliminate deadly meningitis epidemics in sub-Saharan Africa. Methods. From the outset of the project, advocacy and communication strategies were developed and adjusted as the project evolved in Europe, Africa, India, and the United States. Communications efforts were evidence-based, and involved partnerships with the media and various stakeholders including African ministries of health, the World Health Organization, UNICEF, Gavi, the Centers for Disease Control and Prevention, and Médecins Sans Frontières. Results. The implementation of an integrated communication strategy ensured the active cooperation of stakeholders while providing an organized and defined format for the dissemination of project-related developmental activities and the successful introduction of the vaccine. Conclusions. Early in the project, a communications strategy that engaged stakeholders and potential supporters was developed. The strategy was implemented and adapted as the project matured. Linked communication proved to be key to the successful wide-scale introduction of the PsA-TT (MenAfriVac) vaccine in Africa.
format Online
Article
Text
id pubmed-4639482
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-46394822015-11-12 Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa Berlier, Monique Barry, Rodrigue Shadid, John Sirica, Coimbra Brunier, Alison Hasan, Hayatee Bouma, Enricke Clin Infect Dis The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa Background. A new group A meningococcal conjugate vaccine was developed to eliminate deadly meningitis epidemics in sub-Saharan Africa. Methods. From the outset of the project, advocacy and communication strategies were developed and adjusted as the project evolved in Europe, Africa, India, and the United States. Communications efforts were evidence-based, and involved partnerships with the media and various stakeholders including African ministries of health, the World Health Organization, UNICEF, Gavi, the Centers for Disease Control and Prevention, and Médecins Sans Frontières. Results. The implementation of an integrated communication strategy ensured the active cooperation of stakeholders while providing an organized and defined format for the dissemination of project-related developmental activities and the successful introduction of the vaccine. Conclusions. Early in the project, a communications strategy that engaged stakeholders and potential supporters was developed. The strategy was implemented and adapted as the project matured. Linked communication proved to be key to the successful wide-scale introduction of the PsA-TT (MenAfriVac) vaccine in Africa. Oxford University Press 2015-11-15 2015-11-09 /pmc/articles/PMC4639482/ /pubmed/26553674 http://dx.doi.org/10.1093/cid/civ493 Text en © 2015 World Health Organization; licensee Oxford Journals. http://creativecommons.org/licenses/by/3.0/igo/legalcode This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (http://creativecommons.org/licenses/by/3.0/igo/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organisation or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.
spellingShingle The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Berlier, Monique
Barry, Rodrigue
Shadid, John
Sirica, Coimbra
Brunier, Alison
Hasan, Hayatee
Bouma, Enricke
Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa
title Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa
title_full Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa
title_fullStr Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa
title_full_unstemmed Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa
title_short Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa
title_sort communication challenges during the development and introduction of a new meningococcal vaccine in africa
topic The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639482/
https://www.ncbi.nlm.nih.gov/pubmed/26553674
http://dx.doi.org/10.1093/cid/civ493
work_keys_str_mv AT berliermonique communicationchallengesduringthedevelopmentandintroductionofanewmeningococcalvaccineinafrica
AT barryrodrigue communicationchallengesduringthedevelopmentandintroductionofanewmeningococcalvaccineinafrica
AT shadidjohn communicationchallengesduringthedevelopmentandintroductionofanewmeningococcalvaccineinafrica
AT siricacoimbra communicationchallengesduringthedevelopmentandintroductionofanewmeningococcalvaccineinafrica
AT brunieralison communicationchallengesduringthedevelopmentandintroductionofanewmeningococcalvaccineinafrica
AT hasanhayatee communicationchallengesduringthedevelopmentandintroductionofanewmeningococcalvaccineinafrica
AT boumaenricke communicationchallengesduringthedevelopmentandintroductionofanewmeningococcalvaccineinafrica